|Bid||0.00 x 3100|
|Ask||0.00 x 1000|
|Day's Range||17.06 - 18.28|
|52 Week Range||17.06 - 40.00|
|Beta (5Y Monthly)||0.09|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 11, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||69.83|
Subscribe to Yahoo Finance Plus to view Fair Value for RLMDLearn more
Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), announced today that the data related to the recently completed human abuse potential (HAP) study evaluating REL-1017—the company's lead product candidate—versus oxycodone, will be presented in a poster presentation at the 60th Annual Meeting of the American College of Neuropsychopharmacology, which is taking place December 5-8, 2021, in San Juan, Puerto Rico. Th
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update and announced financial results for the three and nine months ended September 30, 2021.